Lauren A. Baldassarre, MD, FACC
Associate Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2026
Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association
Zhang L, Iliescu C, Ferencik M, Finamore V, Beavers C, Patel A, Ghoshhajra B, Milgrom S, Dent S, Baldassarre L, Jaffe I, Lopez-Mattei J, Health O. Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association. Circulation 2026, 153: e916-e933. PMID: 41657216, DOI: 10.1161/cir.0000000000001391.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseCoronary atherosclerosisClonal hematopoiesisRisk stratificationClonal hematopoiesis of indeterminate potentialImmune checkpoint inhibitorsCardiovascular diseaseRisk of cardiotoxicityCoronary artery diseaseNoninvasive imaging modalityInvasive imaging techniquesCheckpoint inhibitorsElevated bleedingScientific statementAmerican Heart AssociationRadiation therapyHormone therapyIndividualized managementThrombotic riskIndeterminate potentialEndothelial dysfunctionIntervention medicationPathophysiological mechanismsArtery diseaseHeart AssociationResearch Priorities and Future Directions in Cardio-Oncology
Mszar R, Ali A, Hull S, Ferrucci L, Baldassarre L, Khera R, Irwin M, Clasen S. Research Priorities and Future Directions in Cardio-Oncology. Current Treatment Options In Oncology 2026, 27: 4. PMID: 41484494, DOI: 10.1007/s11864-025-01366-w.Peer-Reviewed Original ResearchConceptsIndividual health outcomesCancer survivorsSocial determinantsSocial determinants of healthQuality-of-care metricsCardiovascular diseaseCardio-oncology rehabilitationHealthy lifestyle behaviorsDeterminants of healthCancer risk factorsCardio-OncologyRisk factorsEvidence-based strategiesContemporary clinical guidelinesHealth equityLifestyle behaviorsLong-term cardiac surveillanceHealth outcomesHealth disciplinesCardiac radiation exposureTreatment continuumEvidence gapsImmune checkpoint inhibitorsInnovative clinical trialsClinical guidelinesID#: 2211521 Identification of Distinct Cardiac Phenotypes in Autoimmune Rheumatic Disease Patients Using CMR-Based Clustering: Associations with Adverse Outcomes
Csecs I, Tysarowski M, Baig M, Ruiz D, DiGregorio H, Hinchcliff M, Peters D, Baldassarre L, Feher A. ID#: 2211521 Identification of Distinct Cardiac Phenotypes in Autoimmune Rheumatic Disease Patients Using CMR-Based Clustering: Associations with Adverse Outcomes. Journal Of Cardiovascular Magnetic Resonance 2026, 28: 102137. DOI: 10.1016/j.jocmr.2025.102137.Peer-Reviewed Original Research
2025
Myocarditis‐Associated Cardiogenic Shock: A Nationwide Multicenter Study
Zarif T, Ambrosini A, Shahu A, Shen M, Gastanadui M, Safiriyu I, Guha A, Jacobs M, Ali T, Kwan J, Hull S, Baldassarre L, Miller P. Myocarditis‐Associated Cardiogenic Shock: A Nationwide Multicenter Study. Journal Of The American Heart Association 2025, 14: e042850. PMID: 41220123, PMCID: PMC12887199, DOI: 10.1161/jaha.125.042850.Peer-Reviewed Original ResearchConceptsCardiogenic shockClinical outcomesClinical outcomes of patientsInverse probability weightingCoronary Artery Bypass GraftingIn-hospital mortality ratePulmonary artery catheterizationMortality rateOutcomes of patientsLeft heart catheterizationLeft ventricular assist device implantationVentricular assist device implantationCritically Ill PopulationAugmented inverse probability weightingArtery Bypass GraftingCharlson Comorbidity IndexIn-Hospital DeathAssist device implantationCritical care therapiesPercutaneous coronary interventionMechanical circulatory supportRates of cancerHeart catheterizationVizient Clinical Data BaseInotropic medicationsCardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Myocarditis: Diagnostic and Prognostic Evidence and Limitations
Salem J, Baldassarre L, Redheuil A, Boussouar S, Thavendiranathan P, Procureur A. Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Myocarditis: Diagnostic and Prognostic Evidence and Limitations. Current Heart Failure Reports 2025, 22: 28. PMID: 41123742, DOI: 10.1007/s11897-025-00717-w.Peer-Reviewed Original ResearchConceptsCardiac magnetic resonance imagingLate gadolinium enhancementMagnetic resonance imagingCardiac magnetic resonance imaging findingsImmune checkpoint inhibitor myocarditisSeptal late gadolinium enhancementResonance imagingNative myocardial T1Multicenter prospective studyDiagnostic work-upMyocardial involvementGadolinium enhancementMyocardial abnormalitiesPrognostic markerPrognostic associationPrognostic evidenceProspective studyMyocardial edemaPathological dataMyocardial T1Work-upOncology patientsImpaired strainScan timeMethodological limitationsImmune checkpoint inhibitor-associated myocarditis: a novel risk score
Power J, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas N, Lehmann L, Cautela J, Courand P, Hayek S, Zhu H, Zaha V, Cheng R, Alexandre J, Roubille F, Baldassarre L, Chen Y, Baik A, Laufer-Perl M, Tamura Y, Asnani A, Francis S, Gaughan E, Rainer P, Bailly G, Flint D, Arangalage D, Cariou E, Florido R, Narezkina A, Liu Y, Sandhu S, Leong D, Issa N, Piriou N, Heinzerling L, Peretto G, Crusz S, Akhter N, Levenson J, Turker I, Eslami A, Fenioux C, Moliner P, Obeid M, Chan W, Ewer S, Kassaian S, Johnson D, Nohria A, Zadok O, Moslehi J, Salem J, Deswal A, Thuny F, Bouali A, Hughes A, Moser L, Faure M, Vila R, Jimenez J, Kassaian S, Paven E, Galli E, Fernandez T, Cobarro L, Habib M, Tajiri K, Rocher F, Bejan-Angoulvant T, Bilen M, Parashar S, Guha A, Song W, Koenig D, Mertz K, Lenneman C, Haydon A, Lesiuk C, Tresorier R, Samara Y, Grohe C, Dietrich P, Tierney S, Rassy E, Mervoyer E, Suzuki S, Fukushima S, Guha A, Robert-Halabi M, Morimoto R, Tajiri K, Copeland-Halperin R, Layoun M, Wang J, Fernando S, Rota E, Katsume Y, Kiniwa Y, Warner E, Seki N, Ruf T, DeLaune J, Aghel N. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. European Heart Journal 2025, 47: 1050-1062. PMID: 40569849, DOI: 10.1093/eurheartj/ehaf315.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsLeft ventricular ejection fractionImmune checkpoint inhibitor myocarditisLow QRS voltagePrognostic risk scoreRespiratory muscle failureComposite outcomeRisk scoreDepressed left ventricular ejection fractionQRS voltageMultivariate Cox regression modelICI-associated myocarditisLife-threatening myocarditisMyasthenia-like syndromeLow-risk patientsVentricular ejection fractionAssociated with magnitudeMuscle failureCox regression modelsCheckpoint inhibitorsPresenting electrocardiogramPrognostic factorsTroponin elevationEjection fractionMulticentre registryGLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance
Chi K, Song J, Desphande S, Lee P, Soni A, Gonzales-Uribe A, Lessa Y, Morgan A, Chang Y, Lin Y, Akman Z, Nouri A, Rossi R, Babapour G, Varrias D, Parker T, Baldassarre L, Jha A, Muchtar E, Hull S, Kwan J, Nanna M. GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance. JAMA Network Open 2025, 8: e2517541. PMID: 40587132, PMCID: PMC12210086, DOI: 10.1001/jamanetworkopen.2025.17541.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1GLP-1 RAsNew-onset HFAcute kidney injuryEnd-stage kidney diseaseScore matching analysisPrimary preventionMonoclonal gammopathyTransient ischemic attackCohort studyDecompensated HFMGUS diagnosisRA usersKidney injuryHeart failureRA useKidney diseaseIschemic attackEffects of GLP-1 RAsMajor adverse cardiovascular eventsProspective randomized trialsSecondary end pointsRisk of cardiovascular diseaseRetrospective cohort studyAdverse cardiovascular eventsImmune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction
Chen Y, Dolladille C, Rao A, Palaskas N, Deswal A, Lehmann L, Cautela J, Courand P, Hayek S, Zhu H, Cheng R, Alexandre J, Baldassarre L, Roubille F, Laufer-Perl M, Asnani A, Ederhy S, Tamura Y, Francis S, Gaughan E, Johnson D, Flint D, Rainer P, Bailly G, Ewer S, Aras M, Arangalage D, Cariou E, Florido R, Peretto G, Zadok O, Akhter N, Narezkina A, Levenson J, Liu Y, Crusz S, Issa N, Piriou N, Leong D, Sandhu S, Turker I, Moliner P, Obeid M, Heinzerling L, Chang W, Stewart A, Venkatesh V, Du Z, Yadavalli A, Kim D, Chandra A, Zhang K, Power J, Moslehi J, Salem J, Zaha V, Registry I. Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction. JACC CardioOncology 2025, 7: 234-248. PMID: 40246381, PMCID: PMC12046861, DOI: 10.1016/j.jaccao.2025.01.020.Peer-Reviewed Original ResearchLeft ventricular ejection fractionImmune checkpoint inhibitorsPredictors of left ventricular ejection fractionAll-Cause MortalityHeart failureAssociated with 30-day all-cause mortalityDocumented LVEFAssociated with left ventricular ejection fractionReduced left ventricular ejection fractionImmune checkpoint inhibitor initiationImmune checkpoint inhibitor myocarditisHistory of heart failurePre-existing heart failureTransforming cancer treatmentVentricular ejection fractionCox proportional hazards modelsBody mass indexMultivariate logistic regressionTime of hospitalizationProportional hazards modelCheckpoint inhibitorsMyositis symptomsChest radiationCardiotoxic therapiesEjection fractionIntegration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology
Erbay M, Manubolu V, Stein-Merlob A, Ferencik M, Mamas M, Lopez-Mattei J, Baldassarre L, Budoff M, Yang E. Integration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology. Current Cardiology Reports 2025, 27: 51. PMID: 39932640, PMCID: PMC11814013, DOI: 10.1007/s11886-025-02206-x.Peer-Reviewed Original ResearchConceptsRadiation-induced cardiovascular diseaseCoronary artery diseaseCardiovascular diseaseCardiac massComputed tomographyArtery diseaseChest CT scans of patientsCT scans of patientsIncreased risk of CVDInvasive coronary angiographyRisk of cardiovascular diseaseRisk of complicationsScans of patientsCardiovascular Computed TomographySeverity of cardiovascular diseaseNon-invasive imaging toolMonitoring of disease progressionManifestations of diseaseAsymptomatic patientsCardiac deteriorationIschemia evaluationCoronary angiographyPericardial diseaseCardiac changesRisk stratificationDiagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-OncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosis
Academic Achievements & Community Involvement
Clinical Care
Overview
Lauren Baldassarre, MD, is a cardiologist at Yale Medicine and director of the Cardio-Oncology Program at the Yale Cancer Center.
Cardio-oncology is a relatively new field that helps patients manage the cardiac side effects of therapies they’re receiving for cancer treatment (such as chemotherapy, radiation and immunotherapy). The goal of the cardio-oncology program is to diagnose and treat those side effects as early as possible.
Dr. Baldassarre first became interested in cardio-oncology during her cardiology fellowship, and she decided to pursue and complete an additional year of fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. That fellowship focused on advanced cardiac imaging with cardiac MRI and caring for cancer patients with cardiac questions or complications. It was a way for Dr. Baldassarre to combine her interests in women’s heart disease and cardiac imaging, and introduced her to the field of cardio-oncology. In 2013, she arrived at Yale Medicine and became the director of the cardio-oncology program in 2015.
As the director, Dr. Baldassarre’s goals have been to offer care to any patient who might benefit from cardiovascular risk assessment and monitoring not only at the main hospital, but also at Yale Medicine satellite sites, and to expand research and clinical trials that investigate ways to diagnose cardiac complications from cancer earlier.
When meeting with new patients, Dr. Baldassarre takes a thorough history and physical and completes a cardiovascular risk assessment based on the type of cancer therapy they will be receiving. Patients can also expect to undergo some cardiac imaging as part of that risk assessment.
“I really hope to be able to put patients at ease,” says Dr. Baldassarre. “I know that patients are concerned especially when they’re going through so much already.” She walks them through established monitoring and treatments protocols, which may be used to prevent complications or treat them, if they do arise.
In addition to seeing patients, Dr. Baldassarre researches the cardiac side effects of immunotherapy, one of the most promising therapies for cancer. She is also an associate professor (cardiology) at Yale Medicine.
Clinical Specialties
Internal Medicine; Cardiovascular Medicine
Fact Sheets
CT Scan for Coronary Artery Disease
Learn More on Yale MedicineChronic Total Occlusion (CTO)
Learn More on Yale MedicineCoronary Artery Disease (CAD)
Learn More on Yale MedicineHeart Disease in Women
Learn More on Yale Medicine
Board Certifications
Cardiovascular Computed Tomography
- Certification Organization
- Certification Board of Cardiovascular Computed Tomography
- Original Certification Date
- 2012
Yale Medicine News
News & Links
News
- April 09, 2026
Fellow Focus in Four: Ibolya Csecs, MD, Cardiovascular Medicine
- July 28, 2025
Smilow Cancer Hospital Cardio-Oncology Program
- September 18, 2024
Drs. Gallegos and Akintoye Named New Leaders of Yale’s Advanced Cardiac Imaging Fellowship Program
- July 24, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (July 2024)
Get In Touch
Contacts
Appointment Number
Clinic Fax Number
Mailing Address
Cardiovascular Medicine
15 York Street, PO Box 208017
New Haven, CT 06520-8017
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.